Puthumana J, Thiessen-Philbrook H, Xu L, et al. - This multicenter, prospective cohort study was conducted to provide more accurate information concerning risk of long-term progression to kidney failure in hospitalized patients. Overall 1,538 hospitalized patients were enrolled. Using urine samples obtained during outpatient follow-up at 3 months, monocyte chemoattractant protein 1 (MCP-1/CCL2), uromodulin (UMOD), and YKL-40 (CHI3L1) were ascertained. Greater estimated glomerular filtration rate (eGFR) reduction and increased incidence of the composite kidney outcome [chronic kidney disease (CKD) incidence, CKD progression, or end-stage renal disease] was reported in relation to higher MCP-1 and YKL-40 levels, whereas smaller eGFR reductions and reduced incidence of the composite kidney outcome were observed in relation to higher UMOD levels. Increased prognostic accuracy and reclassification were afforded by a multimarker score vs traditional clinical variables alone. Overall, the identification of hospitalized patients at risk for kidney disease progression was enabled by biomarker levels at 3 months post-hospitalization.